The Board Tells a Story the Announcements Only Hinted At
Board data shows 22 open roles at the AI-native pharma company this week, salaries spanning $155,000 to $425,000 with a $250,000 median. Only one new posting appeared in the past seven days — a Vice President, Clinical Operations role at $350,000 to $425,000 — suggesting the slate opened in a concentrated push, not a steady drip. The openings follow a $372 million Series D that valued Formation Bio at $1.7 billion and a November partnership with OpenAI and Sanofi to apply predictive modeling to drug candidate selection.
The Series D brought in Sanofi alongside Andreessen Horowitz, Sequoia, and Thrive. Formation Bio describes itself as an AI-native pharma company built to develop treatments faster by redesigning steps from R&D strategy through clinical trials. Its leadership, including former Pfizer R&D president Michael Dolsten, has argued that discovery productivity has doubled over the past decade while approvals have stalled around 60 per year, a bottleneck the company believes AI can relieve.
A CNBC Television interview noted that a patient recruitment campaign once requiring two months of PhD and clinician time now resolves in minutes with a human in the loop. If that leverage is real, the hiring plan should reflect a shift toward roles that build and oversee those systems rather than staff the manual workflows they replace.
Whether Formation Bio can fill all 22 seats with people who speak both wet-lab biology and production-grade software will determine if its AI-driven model moves from thesis to operating reality. The screen starts now.
Where the 22 Roles Sit
Formation Bio's slate splits across three pillars: clinical development, data and product, and asset leadership. The company's job board lists six roles added in the past week, each carrying a salary band topping out between $307,000 and $425,000. Five of the six sit at director level or above.
| Role | Function | Seniority | Location | Salary Band (USD/year) |
|---|---|---|---|---|
| Vice President, Clinical Operations | Clinical Development | VP | Boston, MA; New York, NY | 350,000–425,000 |
| Medical Affairs Lead, Osteoarthritis | Medical Affairs | Lead | Boston, MA; New York, NY | 325,000–425,000 |
| General Manager (Drug Asset Lead) | Asset Leadership | GM | Boston, MA; New York, NY | 311,000–388,500 |
| Senior Director, Clinical Pharmacology | Clinical Development | Senior Director | Boston, MA; New York, NY | 311,000–388,500 |
| Senior Director or Vice President, Product | Product | Senior Director / VP | New York, NY; Boston, MA | 270,000–353,000 |
| Director, Data Science | Data & AI | Director | Boston, MA; New York, NY | 235,000–307,000 |
Clinical development claims the largest share. The VP of Clinical Operations and the Senior Director of Clinical Pharmacology signal a build-out of the engine that moves assets from IND through late-stage trials. Both roles sit in Boston and New York, matching the company's hub model. The Medical Affairs Lead for osteoarthritis adds a therapeutic-area specialist, a sign that at least one asset is far enough along to need field-facing medical strategy before approval.
Asset leadership appears as a distinct function. The General Manager (Drug Asset Lead) role carries a $311,000–$388,500 band, Zero G Talent's data shows. and sits between the two clinical posts. That placement is deliberate: the GM owns the cross-functional plan for a single program, reporting to the chief portfolio officer. Formation Bio has said publicly that it runs each asset as a self-contained unit; this hire confirms the model is scaling.
Product and data science round out the senior tier. The Senior Director or VP of Product spans both hubs at $270,000–$353,000, according to Zero G Talent's live board. The Director of Data Science sits at $235,000–$307,000, lower than the clinical leads but still director-grade. Both roles point to the company's thesis: software that designs trials, predicts enrollment, and surfaces safety signals faster than human analysts can. The product lead will own the roadmap for that platform. The data science lead will staff the models underneath it.
The remaining 16 roles fill out the pyramid below these six. The distribution suggests a split between senior leadership and individual-contributor or manager-tier hires.
Geography is binary. Every one of the six newest roles lists Boston and New York as co-locations. No remote-only, no West Coast, no international. That constraint narrows the candidate pool but aligns with Formation Bio's lab footprint across its hubs.
The salary bands tell their own story. The $155,000 floor exceeds typical biotech research associate ranges in both metros. The $425,000 ceiling, Zero G Talent's live board reports, matches what large pharmas pay vice presidents with extensive experience. Formation Bio is pricing for talent that has already operated at scale.
Inside the Screen: What Gets Candidates Through
The breadth of the 22 roles — clinical operations, medical affairs, drug asset leadership, clinical pharmacology, product, data science — demands a screening process built to vet both wet-lab rigor and computational fluency. The technical screen cannot be a single template; it must discriminate between a candidate who can design a Phase III protocol and one who can productionize a biomarker model.
Glassdoor hosts 84 Formation Bio interview reviews and 83 posted questions as of 2026, a volume that signals heavy candidate flow. The reviews cluster around the technical screen's depth and the cross-disciplinary expectation. The consistency across dozens of reviews points to a deliberate, repeatable process rather than ad-hoc interviewing.
What distinguishes Formation Bio's screen is the explicit demand for cross-disciplinary fluency. A Director, Data Science candidate isn't just asked to optimize a loss function; they're asked how the model's output changes a dose-escalation decision. A Senior Director, Clinical Pharmacology candidate must explain how they'd structure a data pipeline to feed real-world evidence into an adaptive trial design.
The timeline from application to offer varies. The company's board data shows one role added in the past seven days, suggesting the slate is still active and the screen is iterating.
No public scorecard exists for Formation Bio specifically. But the pattern across the 22 roles makes the screen's architecture legible: it filters for people who can operate at the seams. The candidates who pass don't just know their lane; they know how their lane's output becomes another lane's input.
Market Reaction: Candidates and Analysts Respond
The biotech talent market was already tight. CBRE reported that acquiring top talent across life sciences R&D, manufacturing, and medtech "may not significantly lessen in 2024." BioSpace surveys of 502 industry professionals and 66 talent-acquisition leaders conducted June–July 2024 confirmed sustained hiring pressure. Panda International quantified the surge: an 18% year-over-year increase in biotech job postings. Formation Bio's slate (22 openings across two hubs with a $155,000–$425,000 band) landed in that environment like a stone in a pond.
The compensation data reinforces the market heat. First-party board listings show the Vice President, Clinical Operations role banded at $350,000–$425,000; Medical Affairs Lead at $325,000–$425,000; General Manager (Drug Asset Lead) at $311,000–$388,500; and Senior Director, Clinical Pharmacology at $311,000–$388,500. Even the Director, Data Science seat carries a $235,000–$307,000 band. Those figures sit at or above the 75th percentile for comparable titles in the 2024 BioSpace compensation survey.
Candidate sentiment on forums is mixed but informative. While Reddit discussions about "formation.dev" refer to a separate developer fellowship program, the volume of Formation Bio-specific threads has risen sharply. Common threads: the take-home is "real work, not toy problems"; the behavioral round tests "whether you've actually led a program, not just contributed"; and the timeline from first screen to offer can be under three weeks.
CBRE's 2024 trend report flagged that companies combining AI-native platforms with clinical-stage assets — Formation Bio's model — would disproportionately absorb senior talent because "the skill set doesn't exist in volume." The 22-role cohort, heavy on principal and director titles, matches that prediction. The market is watching whether the company can convert that flywheel into the 45-plus approved drugs its advisors have collectively delivered, and do it at the "radical efficiency" its mission statement promises.
The Board Still Shows 22 Seats
Zero G Talent's live board still shows 22 open roles. One Vice President, Clinical Operations posting appeared in the past week. The median holds at $250,000. The screen keeps running.
Working in frontier tech? Zero G Talent tracks the openings: see every open Formation Bio role, browse frontier tech jobs, the companies hiring, and the people building the field.